Boston Scientific Corporation (BSX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Michael F. Mahoney
|
Chairman, President & CEO | 5.73M | 25.79M | 1965 |
|
Mr. Jonathan R. Monson
|
Executive VP & CFO | 1.47M | 1.71M | 1974 |
|
Mr. Vance R. Brown J.D.
|
EVP, General Counsel & Corporate Secretary | 1.6M | -- | 1970 |
|
Mr. Joseph M. Fitzgerald
|
Executive VP & Group President of Cardiovascular | 2.4M | 23.54M | 1964 |
|
Mr. Arthur Crosswell Butcher
|
Executive VP and Group President of MedSurg & Asia Pacific | 1.98M | 5.38M | 1971 |
|
Mr. Paudie O'Connor
|
Executive Vice President of Global Operations | -- | -- | 1968 |
|
Ms. Emily M. Woodworth
|
Senior VP, Global Controller & Chief Accounting Officer | -- | -- | 1978 |
|
Mr. Adam Smith
|
General Manager of Global Sales & Marketing | -- | -- | -- |
|
Ms. Miriam O'sullivan
|
Senior VP & Chief Human Resources Officer | -- | -- | 1981 |
|
Ms. Brenda Becker
|
Senior Vice President of Global Government Affairs | -- | -- | 1960 |
Boston Scientific Corporation
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 59,000
Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Corporate Governance
Upcoming Events
October 28, 2026 at 12:30 PM UTC
Boston Scientific Corporation Earnings Date
Recent Events
May 21, 2026 at 12:00 AM UTC
SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
